Imlunestrant a next-generation oral SERD overcomes ESR1 mutant resistance in estrogen receptor-positive breast cancer.
新一代口服SERD药物Imlunestrant可克服雌激素受体阳性乳腺癌中的ESR1突变耐药性
期刊:JCI Insight
影响因子:6.1
doi:10.1172/jci.insight.188051
Sherman Shira, Sandusky Zachary M, Russo Douglas, Zak David, Nardone Agostina, Friel Delia, Hermida-Prado Francisco, Heraud Capucine, Kuziel Genevra, Verma Ana, Gaglia Giorgio, Kabraji Sheheryar, Nguyen Quang-De, Santagata Sandro, Fanning Sean W, Jeselsohn Rinath
